VedaBio secured a non-exclusive license from Mammoth Biosciences for its CRISPR-based diagnostic technologies, aiming to enhance its amplification-free diagnostic platform. The collaboration promises to accelerate the development of rapid, sensitive molecular tests addressing real-world clinical needs, particularly in decentralized healthcare settings. Mammoth Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, contributes its intellectual property in CRISPR diagnostics, strengthening VedaBio’s technological foundation to bring novel nucleic acid detection assays to market efficiently.